Log in
Enquire now
‌

FABRICO TECHNOLOGY, INC. SBIR Phase II Award, May 2023

A SBIR Phase II contract was awarded to Fabrico Technology, Inc. in May, 2023 for $561,318.0 USD from the U.S. Department of Defense and Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense.

OverviewStructured DataIssuesContributors

Contents

sbir.gov/node/2576053
Is a
SBIR/STTR Awards
SBIR/STTR Awards
0

SBIR/STTR Award attributes

SBIR/STTR Award Recipient
Fabrico Technology, Inc.
Fabrico Technology, Inc.
0
Government Agency
U.S. Department of Defense
U.S. Department of Defense
0
Government Branch
Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense
Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense
0
Award Type
SBIR0
Contract Number (US Government)
W911SR-23-C-00160
Award Phase
Phase II0
Award Amount (USD)
561,3180
Date Awarded
May 22, 2023
0
End Date
May 23, 2025
0
Abstract

Fabrico Technology, Professor Kevin Dalby, the Johnson & Johnson Centennial Professor of Chemical Biology & Medicinal Chemistry, and Dr. Tamer Kaoud, Research Assistant Professor of Chemical Biology & Medicinal Chemistry, College of Pharmacy, the University of Texas at Austin (UT), have successfully met and exceeded the Phase I technical objectives as specified in the original Phase I solicitation. The UT Team generated pseudotyped lentiviral particles bearing Hantavirus (i.e., HTNV and ANDV) and Vesicular Stomatitis Virus (VSV, as a positive control) glycoproteins. These particles were then utilized in an infection cell-based assay to screen for triptan derivatives that prevented Hantavirus entry via endocytosis pathway inhibition in the mammalian HEK293T, A549, and Caco-2 cell lines demonstrating minimum toxicity. As a proof-of-concept, thePhase I studies showed that tested triptans are safe with minimum non-specific interactions and cytotoxicity. Building on this success, Fabrico Technology and the UT Team intend to continue to develop, research and optimize triptan derivatives that demonstrated the greatest efficacy in Phase I. In this Phase II program, Fabrico Technology and the UT Team intends to collaborate with Professor Bente and Dr. Cajimat of the Galveston National Laboratory at UTMB Galveston to provide and be responsible for the conducting of Hamster animal studies with live virus using the identified triptan inhibitors. The Fabrico Technology, UT, and UTMB team intends to meet all of the technical requirements specified in the original Phase II solicitation, including; investigating the mechanism of action using mammalian cell lines and patient-derived organoids, determining the appropriate dose using in-vivo PK/PD modeling in Hamsters and in-vitro ADME (absorption, distribution, metabolism, and excretion), and performing safety/toxicity and efficacy studies in the same animal model using live Andes hantavirus. Fabrico intends to pursue supplemental funding from the NIH Antiviral Program to expand the UT Austin development and UTMB animal studies.

Timeline

No Timeline data yet.

Further Resources

Title
Author
Link
Type
Date
No Further Resources data yet.

References

Find more entities like FABRICO TECHNOLOGY, INC. SBIR Phase II Award, May 2023

Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.
Open Query Tool
Access by API
Golden Query Tool
Golden logo

Company

  • Home
  • Press & Media
  • Blog
  • Careers
  • WE'RE HIRING

Products

  • Knowledge Graph
  • Query Tool
  • Data Requests
  • Knowledge Storage
  • API
  • Pricing
  • Enterprise
  • ChatGPT Plugin

Legal

  • Terms of Service
  • Enterprise Terms of Service
  • Privacy Policy

Help

  • Help center
  • API Documentation
  • Contact Us
By using this site, you agree to our Terms of Service.